Semaglutide FDA & Regulatory Status (2026)
Published reporting only; not an independently verified live regulatory determination. Sources and review dates are shown for each field.
Author: Chad E. · Last reviewed: 2026-10-17
- FDA compounding category
- Not yet reviewed
- PCAC review and vote
- Not yet reviewed
- 503A bulks list status
- Not yet reviewed
- FDA-approved drug
- The cited GLP-1 comparison identifies semaglutide as FDA approved (Ozempic and Wegovy). Source post
Reviewed: 2026-10-17 - WADA status
- Included in the 2026 Monitoring Program; described as monitored, not prohibited. Source post
Reviewed: 2026-10-17
Recent developments
- Apex Peptides, Federal Agents, and What the September 23 Raid Actually Tells Us About the RUO Sector
- PEPTIDES for Veterans Act 2026: Nancy Mace, the VA, and How Everything Changed
- GLP-1 Peptides Explained: Semaglutide vs. Tirzepatide vs. Retatrutide (Research Guide)
- WADA and Peptides in 2026: The Complete Guide to What's Banned, What's Monitored, and Why It Matters
- 503A vs. 503B: How Peptides Fit Into the U.S. Compounding Framework in 2026 and Beyond
Sourced questions
Is Semaglutide FDA approved?
The cited GLP-1 comparison identifies semaglutide as FDA approved (Ozempic and Wegovy).
Is Semaglutide banned by WADA?
Included in the 2026 Monitoring Program; described as monitored, not prohibited.
Encyclopedia entry · State-law reference
Research use only. Not for human consumption. This page summarizes public regulatory information and is not legal advice.